Please use this identifier to cite or link to this item:
|Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE|
New developments in the allergenicity assessment of food derived from biotechnology
|Authors:||Fernandez, Antonio; Selb, Regina; Hoffmann-Sommergruber, Karin; Lovik, Martinus; Mills, Clare; Moreno, F. Javier CSIC ORCID ; Wal, Jean-Michael||Issue Date:||2016||Citation:||FAAM 2016||Abstract:||The European Food Safety Authority (EFSA) and other international bodies (Codex) define the approaches to be followed for the allergenicity assessment of food and feed derived from biotechnology. As an outcome of the allergenicity assessment, risk assessors estimate whether the novel protein is likely to be allergenic and whether the food derived from biotechnology is likely to be more allergenic than that derived from its appropriate comparator(s). Since it is challenging to predict the allergenicity of novel proteins, a weight-of-evidence approach is followed to provide the assessor with a cumulative body of evidence to a) reduce the uncertainty linked to the allergenicity assessment and, b) enhance the reliability of predictions regarding the allergenic potential of novel protein(s). Currently, EFSA is developing supplementary guidance to better define/clarify specific aspects of the allergenicity assessment requirements. In particular, i) non-IgE-mediated immune adverse reactions to foods; ii) in vitro protein digestibility; and iii) endogenous allergenicity, are addressed. Firstly, celiac disease is a well characterised non-IgE-mediated adverse immune reaction to food, and the food proteins involved, as well as the underlying molecular mechanisms, have been described in detail. Consequently, EFSA is working on defining a strategy to be followed for the assessment of novel proteins¿ potential to cause celiac disease. Secondly, the outcome of in vitro protein digestibility studies is considered relevant information in the weight-of-evidence approach. To date, the ¿pepsin resistance test¿ is commonly accepted for the safety assessment considerations by risk assessors. However, EFSA has previously highlighted its limitations for the allergenicity assessment as well as for its capacity to reflect in vivo digestion conditions. Consequently, EFSA is proactively developing a complementary strategy in order to reduce the resulting uncertainty in the allergenicity assessment. This strategy will be based on state-of-the-art in science, aiming at proposing an enhanced and refined in vitro gastroduodenal digestion test where different physiological conditions will be taken into consideration and more informative read-out procedures will be recommended. Thirdly, high performance methodologies for protein identification and quantification will be proposed as complementary/alternative methods to those based on human sera for the assessment of endogenous allergenicity within the comparative assessment analysis.||Description:||Resumen del trabajo presentado al 4th Food Allergy and Anaphylaxis Meeting, celebrado en Roma (Italia) del 13 al 15 de octubre de 2016.-- et al.||URI:||http://hdl.handle.net/10261/151745|
|Appears in Collections:||(CIAL) Comunicaciones congresos|
Show full item record
Review this work
WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.